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The purpose of this work was to obtain information about
conformational changes of the plasma membrane Ca2-pump
(PMCA) in the membrane region upon interaction with Ca2,
calmodulin (CaM) and acidic phospholipids. To this end, we
have quantified labeling of PMCA with the photoactivatable
phosphatidylcholine analog [125I]TID-PC/16, measuring the
shift of conformation E2 to the auto-inhibited conformation E1I
and to the activated E1A state, titrating the effect of Ca2 under
different conditions. Using a similar approach, we also deter-
mined the CaM-PMCA dissociation constant. The results indi-
cate that the PMCA possesses a high affinity site for Ca2
regardless of the presence or absence of activators. Modulation
of pump activity is exerted through the C-terminal domain,
which induces an apparent auto-inhibited conformation for
Ca2 transport but does not modify the affinity for Ca2 at the
transmembrane domain. The C-terminal domain is affected by
CaM and CaM-like treatments driving the auto-inhibited con-
formation E1I to the activated E1A conformation and thusmod-
ulating the transport of Ca2. This is reflected in the different
apparent constants for Ca2 in the absence of CaM (calculated
by Ca2-ATPase activity) that sharply contrast with the lack of
variation of the affinity for the Ca2 site at equilibrium. This is
the first time that equilibrium constants for the dissociation of
Ca2 and CaM ligands from PMCA complexes are measured
through the change of transmembrane conformations of the
pump.Thedata further suggest that the transmembranedomainof
the PMCA undergoes major rearrangements resulting in altered
lipid accessibility upon Ca2 binding and activation.
Detailed structural information about the plasmamembrane
calcium pump (PMCA)2 is currently lacking. This pump is an
integral part of the Ca2 signaling mechanism (1) and is thus a
crucial component of cell function. It is highly regulated by
calmodulin (CaM),which activates this protein by binding to an
auto-inhibitory region (2) and changes the conformation of the
pump from an inhibited state to an activated one (2, 3).
Information about the structure and assembly of the trans-
membrane domain of an integral membrane protein can be
obtained from an analysis of the lipid-protein interactions. In
this work, we have used a hydrophobic photolabeling method
to study the noncovalent interactions between the membrane
domain of the PMCA and surrounding phospholipids under
different experimental conditions that lead to known confor-
mations. It has been previously demonstrated that both the con-
formation and the activity of the pump protein are preserved in
either solubilizedor reconstitutedpurifiedpreparationscompared
with the native pump located in the erythrocyte (4).
In recent work, we assessed changes in the overall exposure
of PMCA to surrounding lipids by quantifying the extent of
protein labeling by the photoactivatable phosphatidylcholine
analog [125I]TID-PC/16 under different conditions (5). This
showed that labeling of PMCA incubated with Ca2 and cal-
modulin decreases by 25% and incubation with Ca2 alone
increases labeling by more than 50% compared with control
labeling of the PMCA in the absence of Ca2 and CaM. These
results suggest that the PMCA assumes two different E1 con-
formations: one that is auto-inhibited and in which the mem-
brane domain is in contact with a higher amount of lipids (incu-
bating with Ca2 alone, E1I) and one inwhich the enzyme is fully
active (incubating with Ca2-calmodulin, E1A) and exhibits a
more compact transmembrane arrangementwith lesser exposure
to lipids. These data provide the first evidence that there is an
auto-inhibited conformation in P-type ATPases involving both
the cytoplasmic regions and the transmembrane segments.
Activation of PMCA is caused by the binding of CaM to the
C-terminal tail of the pump, leading to dissociation of the auto-
inhibitory domain from its close proximity to the active site.
This removes the self-inhibition of the enzyme and stimulates
the PMCA-mediated Ca2 transport severalfold (6). Previ-
ously, the binding of CaM to PMCAwasmeasured indirectly by
determining the PMCA activity (7). Recently, Liyanage et al. (8)
reported a fluorescence polarization method to measure the
binding of CaMmodified with Oregon Green 488. This was an
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evident improvement because it evaluates CaM binding in
equilibrium instead of at steady-state with PMCA activity.
However, it does not evaluate the binding of CaM itself but of a
modified probe. In this report, we introduce a method that
allows calculation of the dissociation constant for binding of
non-labeled CaM to PMCA.
We employed the photoactivatable phosphatidylcholine
analog 1-palmitoyl-2-[9-[2-[125I]iodo-4-(trifluoromethyldia-
zirinyl)-benzyloxycarbonyl]-nonaoyl]-sn-glycero-3-phospho-
choline [125I]TID-PC/16 that has been previously used to ana-
lyze lipid-protein interfaces (9–11). This reagent partitions in
the phospholipidic milieu and upon photolysis reacts indis-
criminately with its molecular environment. It is thus possible
to directly analyze the interaction between the hydrophobic
membrane-spanning domain of amembrane protein and lipids
belonging to its immediate environment (12–14). Applying
this technique on the PMCA, we were able to measure equi-
librium constants for the dissociation of ligands from PMCA
complexes and to draw structural conclusions about the reg-
ulation of the transport of Ca2 in the presence of different
modulators.
EXPERIMENTAL PROCEDURES
Reagents—All chemicals used in this work were of analytical
grade. Calmodulin was obtained from Calbiochem. Recently
drawn human blood for the isolation of PMCA was obtained
from the Hematology Section of the Hospital de Clínicas Gen-
eral San Martín and from Fundacio´n Fundosol (Argentina).
Blood donation in Argentina is voluntary, and therefore the
donormust provide informed consent for the donation of blood
and the subsequent legitimate use of the blood by the transfu-
sion service.
Purification of PMCA from Human Erythrocytes—PMCA
was isolated from CaM-depleted erythrocyte membranes by
the CaM-affinity chromatography procedure (4) and stored in
20% (w/v) glycerol, 0.005% C12E10, 120 mM KCl, 1 mM MgCl2,
10 mMMOPS-K, pH 7.4 at 4 °C, 2 mM EGTA, 2 mM dithiothre-
itol. Protein concentration after purification was about 10
g/ml. No phospholipids were added at any step along the
purification procedure. The PMCA preparation thus
obtained is devoid of natural phospholipids, as assessed by
the failure to detect inorganic phosphate by the method
described below (see “Phospholipid Quantification”). Solu-
bilization and purification of PMCA preserve transport
activity and maintain the kinetic properties and regulatory
characteristics of the enzyme in its native milieu (4). [Ca2]
was calculated by the program Max Chelator and controlled
with an Orion electrode (OR-9720BNWP).
Preparation of [125I] TID-PC/16—TTD-PC/16 (tin precur-
sor) was a kind gift from Dr. J. Brunner (ETH Zurich, Switzer-
land). [125I]TID-PC was prepared by radioiodination of its tin
precursor according toWeber andBrunner (11). After the reac-
tion was completed, the mixture was extracted with chloro-
form/methanol (2:1, v/v) and [125I]TID-PC/16 was purified by
passage through a silica gel column (2.5 ml) using chloroform/
methanol: water/acetic acid (65:25:4:1, v/v) as solvent. The elu-
tion wasmonitored by TLC/autoradiography, and the fractions
containing the product were dried and stored at20 °C.
Phospholipid Quantification—Phospholipid concentration
was measured according to Chen et al. (15) with some modifi-
cations. Samples and standards containing 10–100 nmol of
phosphorus were dried by heating at 100 °C. Mineralization
was carried out by adding 0.1ml ofHNO3, 0.9ml ofHClO4, and
incubating at 190 °C for 30min. Inorganic phosphatewas deter-
mined after Fiske and Subbarow (16).
Measurement of Ca2-ATPase Activity—ATPase activity
was measured at 37 °C by following the release of inorganic
phosphate from ATP as described previously (4). The incuba-
tion medium was: 80 M DMPC, 120 M C12E10, 120 mM KCl,
30 mM MOPS-K (pH 7.4), 3.75 mM MgCl2, 1 mM EGTA, and
enoughCaCl2 to give the desired final free [Ca2]. The reaction
was started by the addition of ATP (final concentration 2 mM).
Release of Pi was estimated according to the procedure of Fiske
and Subbarow (16).
Labeling Procedure—A dried film of the photoactivatable
reagent was suspended in DMPC/C12E10 mixed micelles (80
and 120 M, respectively) containing 10 g/ml of the mem-
brane protein, 120 mM KCl, 30 mMMOPS-K (pH 7.4), 3.75 mM
MgCl2, 1 mM EGTA, and enough CaCl2 to give the desired final
free [Ca2]. The samples were incubated for 20 min at 37 °C
before being irradiated for 15 min with light from a filtered UV
source (360 nm).
Radioactivity and Protein Determination—Electrophoresis
was performed according to the Tris-Tricine SDS-PAGE
method (17). Polypeptides were stained with Coomassie BlueR,
the isolated bands were excised from the gel, and the incorpo-
ration of radioactivity was directly measured on a -counter.
The amount of protein was quantified by eluting each stained
band as previously described (18), including bovine serumalbu-
min in each gel as a standard for protein quantification. Specific
incorporation was calculated as the ratio between measured
radioactivity and amount of protein determined for each band.
Proteolysis of PMCA—Proteolysis of PMCA was performed
for 5 min in the presence of 25 mM Tris-HCl, pH 7.4 at 37 °C, 2
mM EGTA, and 0.22 g/ml of TLCK-treated chymotrypsin in
water. The reaction was stopped by a 10-fold excess of ovomu-
coid trypsin inhibitor solution at 4 °C.
Data Analysis—All measurements were performed in tripli-
cate to quintuplicate unless specified otherwise in the figures.
RESULTS
Incorporation of [125I]TID-PC/16 as a Conformation Marker—
We first wished to determine the extent of [125I]TID-PC/16
labeling of the PMCA in itsmajor knownconformational states.
The E2 state is attained by incubating the PMCA in the absence
of Ca2 (1 mM EGTA). The incorporation of [125I]TID-PC/16
in this condition was considered as the control and was set as
100% (Fig. 1). The other two conformers are E1I, which is
obtained by incubating the enzyme in the presence of Ca2 and
binds themaximumconcentration of [125I]TID-PC/16 (180%at
optimal concentration of Ca2, Fig. 1) and E1A, a conformation
attainable in the presence of Ca2 and CaM or with a CaM-like
effector such as phosphatidic acid, oleic acid or after removal of
the C terminus of PMCA. This conformation binds the least
amount of [125I]TID-PC/16 (75% of the control for E1A
obtained with Ca2 and CaM) (Fig. 1). These data are as
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reported earlier (5) and illustrate the sensitivity of the incor-
poration of labeled [125I]TID-PC/16 on the different PMCA
conformations.
Titration of the E2 to E1I Conformer Shift with Ca2—To
determine the [Ca2] dependence of the conformational shift
from the E2 to the E1I state, we performed a titration experi-
ment (Fig. 2A) inwhichwemeasured the specific incorporation
of [125I]TID-PC/16 to PMCA when the enzyme was incubated
in the presence of increasing concentrations of Ca2. In this
experiment, we titrate the concentration of [125I]TID-PC/16
that binds to PMCAas it shifts from theE2 to the E1I conformer,
i.e. as [125I]TID-PC/16 incorporation increases from 100% to
near 180%. As illustrated in Fig. 2A, [125I]TID-PC/16 incorpo-
ration increases hyperbolicallywith low concentrations ofCa2
(up to 40 M) and then decreases to a level that cannot be
easily evaluated with the available information. However, the
data are well described by Equation 1.
PCB
PC0KCa2 PCmaxCa
2
1
KCa2
[Ca2]

Ca2
Ki
(Eq. 1)
This empirically derived equation aims to characterize the
effect of Ca2 on the amount of [125I]TID-PC/16 bound to
PMCA ([PCB]). PCmax is the maximal value of [PCB] attainable
if [Ca2] Ki (the constant describing the half-maximal con-
centration of Ca2 for inhibition of [125I]TID-PC/16 binding to
PMCA). The term [Ca2]/Ki was included to account for the
inhibitory effect by excess Ca2 (see Fig. 2) and thus to allow a
better estimation of KCa2 (the concentration of Ca2 for half-
maximal binding of [125I]TID-PC/16 toPMCA) andof themax-
imal increase of [PCB], i.e. PCmax PC0, (where PC0 is the
amount of [125I]TID-PC/16 bound in the absence of Ca2). Fit-
ting the experimental data points to this equation yielded
PC0	 99.1
 4.8%, PCmax	 176.7
 4.3%,KCa2	 0.52
 0.14
M, and Ki	 1212
 319 M.
The inset in Fig. 2A shows the specific incorporation of
[125I]TID-PC/16 to PMCA at very low concentrations of Ca2
to illustrate the rapid increase in binding of [125I]TID-PC/16 at
submicromolar [Ca2]. It is also worth pointing out that after
reaching a maximum near 40–50 M Ca2, [125I]TID-PC/16
binding decreases slowly with [Ca2] in a similar way as is
observed when measuring the Ca2-ATPase activity (Fig. 2B).
It was reported earlier that excess [Ca2] in SERCA also
induced a conformation different from that attained at lower
concentrations of Ca2 (19).
Fig. 2B shows the Ca2-ATPase activity as a function of
Ca2. The data were quantitatively evaluated using Equation 2,
 
Ca2Vmax
Ca2 KCa2
Ca22
Ki
(Eq. 2)
where Vmax is the maximum velocity, KCa2 is the apparent
dissociation constant for Ca2 (Ca2 concentration at half-
maximal ATPase activity), and Ki is the concentration of Ca2
for half-maximal inhibition of the enzyme at high [Ca2]. Equa-
tion 2 is an empirical equation, which describes the effect of
Ca2 on Ca2-ATPase activity and takes into account the
inhibitory effect by excess Ca2. It is analogous to Equation 1,
which describes the effect of Ca2 on the incorporation of
[125I]TID-PC/16 into PMCA. It can
be seen from Fig. 2B that the Ca2-
ATPase activity increases hyperbol-
ically with low concentrations of
Ca2 (up to about 50 M) and then
decreases at higher [Ca2] reflect-
ing excess substrate inhibition.
Applying Equation 2 to the data
yielded Vmax 	 13.4 
 1.1 mol Pi
mg1min1, KCa2 	 11.0 
 1.7
M, and Ki	 248
 65 M.
The most interesting finding
resulting from a comparison of the
Ca2 dependence of [125I]TID-PC/
16 incorporation (Fig. 2A) and
ATPase activity (Fig. 2B) is that the
K0.5 for the binding of [125I]TID-
PC/16 is much lower (0.5 M)
than the KCa2 for Ca2 activation
FIGURE 1. Relative specific incorporation of [125I]TID-PC/16 to PMCA
under different conditions. Incorporation in the presence of 1 mM EGTA is
taken as 100% control (E2, left bar).Middle, 15 M Ca
2 (E1I). Right, 5 M Ca
2
and 200 nM calmodulin (E1A). A similar result for E1Awas obtainedwith phos-
phatidic acid, oleic acid, or removing the PMCA C-terminal domain with chy-
motrypsin. Data are the mean
 S.E. of 6–9 independent experiments.
FIGURE 2. [Ca2] dependence of incorporation of [125I]TID-PC/16 to PMCA and of PMCA activity. A, puri-
fied PMCAdevoidof CaMwas incubated in thepresenceof different amounts of Ca2, and after 3min [125I]TID-
PC/16 was added as described under “Experimental Procedures.” The inset shows the incorporation of TID-PC
at low concentration of Ca2. B, Ca2-dependent ATPase activity as a function of [Ca2]. The inset shows the
data at low concentrations of Ca2.
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of the PMCA (11 M). This strongly suggests that the intrinsic
Ca2 affinity of the PMCA in equilibrium is very different from
its apparent Ca2 affinity for activation by Ca2.
Titration of the Ca2Dependence of the E2 to E1A Conformer
Shift in the Presence of Calmodulin and Calmodulin-like
Treatments—We next wished to compare the Ca2 depen-
dence of the E2 E1I shift with that of the shift from E2 to the
activated E1A conformation of the PMCA. To this end, we per-
formed a series of titrations of [125I]TID-PC/16 incorporation
in the presence of various activators of the pump.We chose the
well-known “prototypical” PMCAactivator CaM, the lipid acti-
vators phosphatidic acid (PA) and oleic acid (OA), as well as
limited proteolytic treatment using TLCK-chymotrypsin. The
latter treatment results in a C-terminally truncated and fully
active pump lacking its auto-inhibitory tail (20). These activa-
tors thus reflect different mechanisms and pathways of PMCA
activation.
Activation in the Presence of CaM—Fig. 3A shows the incor-
poration of [125I]TID-PC/16 as a function of concentration of
Ca2 in the presence of 1 M CaM. Initially, incorporation of
[125I]TID-PC/16 decreases rapidly with [Ca2] and then slowly
decreases to a constant value. The experimental data are well
described by Equation 3,
PCB PCmin
PC0 PCmin
1 Ca2KCa2 
n (Eq. 3)
where [PCB] is the [125I]TID-PC/16 bound to PMCA at a given
concentration of ionic calcium; [PCmin] is the final minimal
concentration (%) of [125I]TID-PC/16 bound to PMCA (at non-
limiting concentration of Ca2), [PC0] is the initial concentra-
tion (%) of PC bound to PMCA (at zero [Ca2]), “n” is the Hill
coefficient, and KCa2 is the concentration of Ca2 for half-
maximal binding to PMCA. This empirical equation describes
the binding of [125I]TID-PC/16 to PMCA as a function of Ca2.
It can be seen from Fig. 3A that the amount of [125I]TID-PC/16
bound to PMCA decreases in a sigmoidal fashion with [Ca2]
FIGURE 3. [Ca2] dependence of the incorporation of [125I]TID-PC/16 to PMCA in various activating conditions. A, purified PMCA was incubated in the
presence of different amounts of Ca2 and 1 M CaM, and after 3 min, [125I]TID-PC/16 was added as described under “Experimental Procedures.” Inset,
Ca2-dependent ATPase activity as a function of Ca2 in the presence of CaM. B, Ca2 dependence of the incorporation of [125I]TID-PC/16 to PMCA in the
presence of 58 M phosphatidic acid. Inset, Ca2-ATPase activity as a function of [Ca2] in the presence of phosphatidic acid. C, [Ca2] dependence of the
incorporation of [125I]TID-PC/16 to PMCA in the presence of 10 M oleic acid. Inset, Ca2-ATPase activity as a function of [Ca2] in the presence of oleic acid.
D, [Ca2] dependence of the incorporation of [125I]TID-PC/16 to PMCA submitted to proteolysis with chymotrypsin as described under “Experimental Proce-
dures.” Inset, Ca2-ATPase activity of chymotrypsin-truncated PMCA as a function of [Ca2].
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from 100% (PC0, in the absence of Ca2) to a constant minimal
value (PCmin, at non-limiting concentration of Ca2), which
indicates that the PMCA conformation in this latter condition
is more compact than that in the absence of Ca2. Evaluating
the data with Equation 3 yielded the following experimental
parameters: [PCmin]	 76.7
 0.5%, [PC0]	 100.2
 0.5%, n	
1.7
 0.2, and KCa2 	 0.46
 0.04 M.
The inset in Fig. 3A shows the CaM-stimulated Ca2-
ATPase activity as a function of concentration of Ca2. The
experimental points were adjusted to a simple hyperbolic
function with a Vmax of 12.8
 0.2 mol Pi mg1min1, and
KCa2 	 0.75 
 0.07 M.
In contrast to the large difference between the equilibrium
Ca2 affinity and the steady state (apparent) Ca2 affinity for
ATPase activation by Ca2 alone (E2-E1I shift), the Ca2 affin-
ity for CaM stimulation of [125I]TID-PC/16 incorporation dur-
ing the E2-E1A conformational shift is much closer to the true
equilibrium Ca2 affinity of the pump.
Activation in the Presence of Phosphatidic Acid—Fig. 3B
shows the incorporation of [125I]TID-PC/16 as a function of
concentration of Ca2 in the presence of 58M PA. Incorpora-
tion of [125I]TID-PC/16 decreases with [Ca2] in a sigmoidal
manner and then reaches a constant minimal value. Applying
Equation 3 yielded [PCmin]	 91.2
 0.4%, [PC0]	 99.8
 0.5,
n	 3.7
 0.9, and KCa2 	 0.67
 0.05 M.
Whereas the values for most parameters are similar for the
PA- and CaM-stimulated E2-E1A transition, the value of n
describing the sigmoidicity of the Ca2 dependence is much
higher for PA than for any of the other treatments. Equation 3 is
a Hill equation that shows in the denominator term the expo-
nent n for the Ca2 concentration, where n can be higher than
one. In fact the value for n is near 2 for the effect of Ca2 on
[125I]TID-PC/16 binding in the presence of CaM (as well as of
OA and for the enzyme that lacks the C-terminal region; see
below), indicating that more than one molecule of Ca2 is
needed for the E2 to E1A shift. However, in the presence of PA,
n is near 4 for the effect of Ca2 on [125I]TID-PC/16 binding.
This may be caused by a more complex behavior between PA
and Ca2: (i) PA could be at a non-optimal concentration and
(ii) PA could associate with free Ca2. However, when wemea-
sured the concentration of Ca2 with a Ca2-sensitive elec-
trode in the absence and in the presence of 60 M of PA, we
found the value for free [Ca2] to be similar.We also determined
the [125I]TID-PC/16 binding to PMCA as a function of PA, and
the results indicate that the concentration used in the experi-
ments of this work is sufficient to obtain themaximal effect, i.e.
to reach PCmin (data not shown).
Measuring the PA-stimulated Ca2-ATPase activity as a
function of concentration of Ca2 (inset in Fig. 3B) yielded a
Vmax of 11.3 
 0.2 mol Pi mg1min1, and KCa2 	 0.83 

0.07 M. These values are comparable to those determined for
the activation of the PMCA by CaM and indicate that the
apparent Ca2 affinity for activation by either mechanism
approaches the equilibrium Ca2 affinity of the PMCA.
Activation in the Presence of Oleic Acid—The incorporation
of [125I]TID-PC/16 as a function of concentration of Ca2 in
the presence of 10 MOA is shown in Fig. 3C. As in the case of
PA, incorporation of [125I]TID-PC/16 decreases with Ca2 and
then reaches a constant value. Using Equation 3 to evaluate the
experimental points resulted in [PCmin]	 83.5
 3.6%, [PC0]	
100.3
 2.3%, n	 1.8
 1.1, and KCa2 	 0.75
 0.28 M.
The inset in Fig. 3C shows the Ca2-ATPase activity in the
presence of 10 MOA as a function of Ca2. The experimental
points were adjusted to a simple hyperbolic function yielding a
Vmax of 11.1 
 0.3 mol Pi mg1min1, and KCa2 	 0.96 

0.14 M.
Removal of the PMCAC-terminalDomain by Proteolysis with
TLCK-chymotrypsin—As mentioned above, proteolysis of
PMCA by chymotrypsin yields a pump that is fully active, lacks
the C-terminal region, and hence does not bind CaM.We used
TLCK-chymotrypsin to avoid digestion of the N-terminal
domain, which remains intact based on the reaction of the
truncated PMCA with the specific antibody JA9 (5). Fig. 3D
shows the incorporation of [125I]TID-PC/16 to chymotryp-
sin-treated PMCA as a function of [Ca2]. Equation 3 was
again fitted to the experimental points, yielding [PCmin] 	
83.6 
 0.6%, [PC0] 	 100.2 
 1.2%, n 	 2.3 
 0.5, and
KCa2 	 0.79 
 0.10 M.
The Ca2-ATPase activity as a function of [Ca2] of the
C-terminally truncated pump is shown in the inset of Fig. 3D.
Adjusting the experimental points to a simple hyperbolic
function gave a Vmax of 13.9
 0.4 mol Pi mg1min1, and
KCa2 	 0.53 
 0.07 M.
Comparison of ApparentCa2Affinities for PMCAMeasured
in Equilibrium and in the Steady State—Table 1 summarizes
the results of the experiments described above and compares
the Ca2 affinities obtained through binding of [125I]TID-PC/
16 and through the determination of Ca2-ATPase activity in
similar experimental conditions. From an inspection of this
table we can draw the following conclusions: 1) Treatments
TABLE 1
Apparent Ca2 affinities determined by enzyme activity and by specific [125I]TID-PC/16 incorporation under equilibrium conditions
Results represent the mean
 S.E. of 4–9 independent experiments by triplicate. E1A: an activated state of E1; E1I: an inhibited state of E1. PA: phosphatidic acid; OA: oleic
acid; Chym: a 120-kDa PMCA devoid of the C-terminus obtained after chymotrypsin digestion.
Condition Conformation Ca
2-ATPase activity Specific incorporation of [125I]TID-PC/16
KCa2 Vmax KCa2 [PC0]-[PCmax] or [PC0]-[PCmin]a
M mol Pi mg1.min1 M %
Ca2 E1I 11.0
 1.7 13.4
 1.0 0.52
 0.14 77
 4b
Ca2 CaM E1A 0.75
 0.07 12.8
 0.2 0.46
 0.04 24
 1
Ca2  PA E1A 0.83
 0.07 11.3
 0.2 0.67
 0.05 9
 1
Ca2 OA E1A 0.96
 0.14 11.1
 0.3 0.75
 0.28 17
 1
Ca2  Chym E1A 0.53
 0.07 13.9
 0.4 0.79
 0.10 17
 1
a [125I]TID-PC/16 bound to PMCA increases or decreases with [Ca2] from 100% (PC0, [125I]TID-PC/16 bound in the absence of Ca2) to a newmaximum or minimum value
(PCmax or PCmin, [125I]TID-PC/16 bound at non-limiting concentration of Ca2) as indicated by Eq. 1 and 3.
b The negative value reflects the fact that for Ca2 alone, PCmax is higher than PC0.
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that alter the equilibrium between E1 and E2 are recognized by
a change in the incorporation of the probe. 2) Ca2 affinities
correlate well between the two methods employed when CaM
or CaM-like treatments modified the PMCA. However, 3) The
affinity for Ca2 alone is similar to that in the presence of CaM
or CaM-like treatments only when this parameter is evaluated
according to [125I]TID-PC/16 incorporation on PMCA under-
going the shift between E2 to E1A or E2 to E1I. Taken together,
these results indicate that the affinity for Ca2 of the PMCA is
not regulated at the Ca2 site in the membrane but rather
through the auto-inhibitory cytoplasmic domain.
Titration of the E1I to E1A Conformer Shift with Calmodulin—
Activation of the PMCA is due to the binding of CaM, which
dissociates the auto-inhibitory domain, removes the self-inhi-
bition by the enzyme and thus stimulates PMCA transport sev-
eralfold (6). One way to measure the binding of CaM to the
PMCA has been to follow pump activity as a function of the
CaM concentration (7). We measured the binding of CaM to
PMCAby quantifying the amount of bound [125I]TID-PC/16 to
PMCA as a function of [CaM] in the presence of a saturating
concentration of Ca2. Fig. 4 shows the CaM-dependent incor-
poration of [125I]TID-PC/16 in the presence of 100 M Ca2.
Equation 3 was fitted to the experimental points, but now the
variable was the concentration of CaM instead of the concen-
tration of Ca2. Accordingly, KCa2 of Equation 3 is replaced
by KD(CaM) and [PC0] reflects the initial amount of [125I]TID-
PC/16 bound in the absence of CaM rather than in the absence
of Ca2. This resulted in the following values: [PCmin]	 71.9

1.8%, [PC0]	 154.8
 2.6%, n	 1.9
 0.2, andKD(CaM)	 9.6

0.8 nM.
The inset shows the Ca2-ATPase activity as a function of
[CaM]. The experimental points were fitted to a hyperbolic
function plus a termVo that indicates theATPase activity in the
absence of CaM, yielding Vo	 4.9
 0.5 mol Pi mg1min1,
Vmax	 12.5
 0.6 mol Pi mg1min1, and KD(CaM)	 7.2

1.4 nM. These results show that the values for the dissociation
constant of CaM calculated from the change in [125I]TID-PC/
16 incorporation and from enzyme activation are very similar,
validating the use of [125I]TID-PC/16 incorporation to follow
the conformational shift from E1I to E1A.
DISCUSSION
[125I]TID-PC/16 has previously been used to identify and
characterize regions within membrane proteins that interact
with lipids (11, 14). Its physicochemical behavior in terms of
mobility in thin layer chromatography is indistinguishable from
PC, and its interaction with the transmembrane region of inte-
gral membrane proteins also appears to be identical to that of
PC (12, 13). PC is generally chosen as the reference lipid against
which relative lipid association constants of integral membrane
proteins are compared, because these proteins show no selec-
tivity for this phospholipid (21). This fact simplifies the inter-
pretation of our results, as it allows a direct correlation between
level of reagent incorporation and amount of protein surface
exposed to surrounding lipids.
By using [125I]TID-PC/16 as a sensitive probe of the hydro-
phobic protein environment, we were able to study the trans-
membrane region of the PMCA in different conformations.
Quantification of the amount of labeling by [125I]TID-PC/16
then allowed us to calculate the apparent affinity of the PMCA
for Ca2 and CaM as the pump shifts between different con-
formers in equilibrium with surrounding lipids.
Activation of the PMCA by CaM is commonly explained by
the binding of CaM to the CaM binding domain in the C-ter-
minal tail of the pump, followed by release of the inhibitory
interactions from the cytosolic core. It should be noted that this
hypothesis for themechanism of auto-inhibition and activation
does not predict changes in the transmembrane region. How-
ever, in a previous report, we demonstrated that the auto-inhib-
ited conformation is distinct in its membrane domain, and that
the conformational changes induced by auto-inhibition do
expose additional hydrophobic surfaces of the protein to phos-
pholipids. The auto-inhibited conformation was also obtained
by adding the CaM-binding peptide C28 to an E1CaCaM state
of PMCA (corresponding to the activated pump), showing the
reversibility of this conformational transition (5). On the basis
of these observations we postulated that the PMCA possesses
two different E1-Ca2 conformations: one that is auto-inhib-
ited and is in contact with a higher amount of lipids (incubating
with Ca2 alone, E1I) and one in which the enzyme is fully
active (incubating with Ca2-calmodulin, E1A) and that exhib-
its amore compact transmembrane arrangementwith a smaller
surface area exposed to lipids.
According to kinetic enzyme activitymeasurements the acti-
vated conformer E1A can be obtained in the presence of CaM,
acidic phospholipids, unsaturated fatty acids, protein oligomer-
ization, or after removing the C-terminal tail by controlled pro-
teolysis, e.g. with chymotrypsin (2, 4, 6, 22). In this report, we
used several of these activatingmodes to compare the apparent
affinity of the PMCA for Ca2 as determined in two entirely
different ways: (a) by evaluating the K0.5(Ca2) for activation of
the Ca2-ATPase activity, i.e. in steady-state conditions of the
enzyme, and (b) by measuring the equilibrium constants that
drive the conformer E2 to E1A as reflected in a change in
FIGURE 4. Calmodulin dependence of the incorporation of [125I]TID-PC/
16 to PMCA in the presence of saturating concentration of Ca2. Incor-
poration of [125I]TID-PC/16 was determined in a medium containing 100
M Ca2 at 37 °C. Inset, Ca2-ATPase activity as a function of the CaM
concentration.
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[125I]TID-PC/16 incorporation. The results clearly show that
the PMCA possesses a high-affinity site for Ca2 (KD0.5 M)
regardless of the presence or absence of activators. Therefore,
modulation of the pump activity is exerted through the C-ter-
minal domain, which induces an auto-inhibited conformation
but does not modify the affinity for Ca2 at the site where it
binds for transport into the transmembrane domain. This find-
ing is analogous to an earlier study on the cardiac muscle
SERCA (SERCA2a), which showed that the equilibrium Ca2
binding affinity of the pump was unaffected by the inhibitory
protein phospholamban (23). Similar to CaM activation of the
PMCA, phospholamban phosphorylation stimulates SERCA
activity by releasing the inhibitory interaction, which is
reflected in an increase in the apparent Ca2 affinity of the
pump.
Ca2-ATPase activation yields an “apparent” affinity for
Ca2, which is not the same as the actual binding affinity under
equilibrium conditions. Our approach measures the real sub-
strate affinity forCa2 in different conditions through the bind-
ing of [125I]TID-PC/16, which is directly proportional to the
transmembrane surface of PMCA exposed to surrounding lip-
ids. These two affinities should not be compared directly
because they are determined in different states of the system.
The experiments of this paper were designed to show that the
true affinity of PMCA for Ca2 is high, a fact that is masked by
the steady-state condition, which shows a low affinity site for
Ca2.
Our findings raise interesting questions concerning the
structural features of the transmembrane region of the PMCA
in its auto-inhibited versus activated E1-Ca conformation. In
the SERCA pump, for which atomic-resolution structural
information is available for several conformers in both the E1
and E2 state (24–28), calculations of the membrane-embedded
accessible surface area revealed only relatively modest differ-
ences between different Ca2-bound E1-conformers (5). Major
rearrangements involving the membrane-spanning region are,
however, observed upon the E1 to E2 (or E2-E1) transition of the
enzyme cycle. Because of the gross architectural similarity of
the PMCA to the SERCA, it is assumed that comparable struc-
tural rearrangements accompany the reaction cycle in the
PMCA, including large domain movements of the A (actuator)
andN (nucleotide-binding) domains with respect to each other
and the P (phosphorylation) cytosolic domain. Our data based
on the changes in [125I]TID-PC/16 lipid binding to the PMCA
clearly suggest that a major difference exists in the membrane
domain of the pump in the auto-inhibited E1-Ca conformation
(E1I) compared with the activated E1-Ca (E1A) conformation
where the auto-inhibitory tail is dissociated from the core of the
enzyme. The most salient difference between the SERCA and
PMCApumps is the presence of the extendedC-terminal tail in
the PMCA that encompasses the auto-inhibitory region. How
could the presence of this tail, which is thought to be cytosolic,
have such a dramatic effect on the membrane portion of the
PMCA? Cross-linking studies have shown that in the auto-in-
hibited state, the tail is in close proximity to sequences in both
the A- and N-domain (29, 30) and FRET studies indicate that
theN andC termini of the pump are separated by less than 50Å
in the inhibited state (3). Thus, in the inhibited E1I conforma-
tion where the C-tail is “clamped-down” on the A- and N-do-
mains, the transmembrane domain of the PMCA may be
uniquely different from that in the E1-Ca state of SERCA and of
the activated E1A state of the PMCA. Indeed, we found that any
of the activating treatments (CaM, phosphatidic or oleic acid,
and limited chymotrypsin proteolysis) resulted in a comparable
(albeit not identical) change in [125I]TID-PC/16 incorporation
to PMCA, suggesting that the common denominator is the
release of the auto-inhibitory tail to allow a shift to the E1A
conformer. Although a better understanding of the differences
in the membrane domain of the E1I and E1A conformers of the
PMCA will require higher resolution structural information,
the data strongly suggest that substantial differences exist in the
arrangement of the transmembrane domain in the PMCA in
comparison with the SERCA pump, at least in the auto-inhib-
ited E1 state of the PMCA. We cannot exclude the possibility
that CaM, PA, OA, and partial proteolysis affect the membrane
domain of the PMCA in a different manner and to a different
degree. In fact, incorporation of [125I]TID-PC/16 to PMCA is
different in the presence of CaM or PA. Experiments involving
[125I]TID-PC/16 labeling and proteolysis with V8 protease
show that labeling of PMCA with CaM affects transmembrane
segments 3 and 4 and the bundle of TM 5 to 10, whereas in the
presence of PA transmembrane segments 1–2 and 3–4 are
mostly responsible for the incorporation of [125I]TID-PC/16.3
Therefore, the definition of the characteristics of the conformer
E1A is purely operational and involves a series of structurally
different conformers with a similar apparent high affinity for
Ca2.
Using a similar approach as for the determination of Ca2
affinities we followed the transition from E1I to E1A by titrat-
ing this conformational shift with CaM. This allowed us to
calculate the dissociation constant for binding of native non-
labeled CaM to PMCA in equilibrium. The resulting value of
9.6 
 0.8 nM is similar to the KD for CaM obtained in steady
state conditions by evaluating the half-maximal activation of
Ca2-ATPase (7.2 
 1.4 nM measured in this study (Fig. 4),
11.6 
 2.4 nM, reported by Penheiter et al. (31)). This indi-
cates that the apparent affinity for CaM is indistinguishable
in steady state and in equilibrium experiments. Recently,
Liyanage et al. (8), using a fluorescence polarization assay to
evaluate the binding of a modified CaM to the PMCA, deter-
mined a KD of 5.8 
 0.5 nM, a value comparable to the one
obtained in this work. However, it is possible that the small
difference in these KD values is attributable to different
sources of CaM or to the Oregon Green 488 modified CaM
used in their method. Regardless, our approach allows an
independent calculation of the dissociation constant of non-
labeled CaM from the PMCA.
The data presented here represent the first example where
equilibrium constants for the dissociation of ligands from
PMCA complexes are measured through the change of trans-
membrane conformations of the pump. The method is sensi-
tive, precise, and requires a very low amount of protein. This
should enable its application to other membrane proteins that
3 I. Mangialavori, A. Villamil-Giraldo, M. Ferreira-Gomes, A. Caride, and J. P.
Rossi, unpublished observation.
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cycle through different conformations, such as all members of
the P-type ATPase family. Experiments are currently underway
using this methodology to evaluate the affinity constants of
PMCA for ATP under different experimental conditions.
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